This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

EfficacyEfficacyKey Take AwaysHospitalisation DataSafetySafetyAdverse Event Management: VOD/SOSSelected Adverse ReactionsDosingDosing and Dose ModificationsAdministrationSupport and ResourcesPublications
BESPONSA® (inotuzumab ozogamicin)

BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).1

Clinical Study Results

The efficacy and safety of BESPONSA were evaluated in a Phase 3 clinical trial vs standard chemotherapy.1,2

 Review efficacy data Loading BESPONSA Safety Profile

Review the safety profile of BESPONSA.1

 Review safety data Loading Dosing & Administration

Besponsa is a 1-hour IV infusion and can conveniently be administered in the outpatient setting.1,3

 Learn more about dosing Loading
Besponsa Prescribing Information
 Visit LoadingALL=acute lymphoblastic leukemia; CD=cluster of differentiation; CR=complete remission; EMD=extramedullary disease; Ph+=Philadelphia chromosome-positive; R/R=relapsed/refractory; SmPC=Summary of Product Characteristics; TKI=tyrosine kinase inhibitor.
References:Besponsa Summary of Product CharacteristicsKantarjian HM, DeAngelo DJ, Stelljes M, et al.. N Engl J Med. 2016;375(8):740-753.Marks DI, et al. Cancer Med. 2019;8(13):5959-5968

Legal Category: S1A
Further information is available upon request

PP-INO-IRL-0104 January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.